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Abstract
Recent genome-wide association studies have identified several single nucleotide polymor-
phisms (SNPs) associated with glucose levels. We tested the hypothesis here whether the
cumulative effect of glucose raising SNPs, assessed via a score, is associated with glucose
levels. A total of 1,434 participants of Greek descent from the THISEAS study and 1,160
participants form the GOMAP study were included in this analysis. We developed a genetic
risk score (GRS), based on the known glucose-raising loci, in order to investigate the cumu-
lative effect of known glucose loci on glucose levels. In the THISEAS study, the GRS score
was significantly associated with increased glucose levels (mmol/L) (β ± SE: 0.024 ± 0.004,
P = 8.27e-07). The effect of the genetic risk score was also significant in the GOMAP study
(β ± SE: 0.011 ± 0.005, P = 0.031). In the meta-analysis of the two studies both scores were
significantly associated with higher glucose levels GRS: β ± SE: 0.019 ± 0.003, P = 1.41e-
09. Also, variants at the SLC30A8, PROX1, MTNR1B, ADRA2A, G6PC2, LPIN3 loci indi-
cated nominal evidence for association with glucose levels (p < 0.05). We replicate associa-
tions of the established glucose raising variants in the Greek population and confirm
directional consistency of effects (binomial sign test p = 6.96e-05). We also demonstrate
that the cumulative effect of the established glucose loci yielded a significant association
with increasing glucose levels.
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Introduction
Type 2 diabetes is a metabolic disorder resulting in altered protein, carbohydrate and fat
metabolism and is characterized by impaired insulin secretion, impaired glucose and insulin
homeostasis. Pre-diabetic abnormalities, such as impaired fasting glucose and impaired glu-
cose tolerance could lead to diabetes [1–3]. A large number of genome-wide significant loci
influencing glycemic traits [4] and type 2 diabetes development [5, 6] have been recently iden-
tified. The results from these studies highlight important biological pathways implicated in
glucose regulation [7, 8]. The number of common associated SNPs with fasting glucose con-
centration has now raised to 36[9]. Many of these loci include those encoding genes involved
in b-cell function, insulin secretion and some are encoding transcription factors implicated in
pancreas development[4]. A number of the loci associated with glycemic traits in diabetes-free
individuals also affect the risk of type 2 diabetes [10]. More specifically, thirty three out of 53
glycemic loci are also associated with increased type 2 diabetes risk [4]. The fact that the
observed effect sizes are generally small lends further support that a significant number of vari-
ants with small effect size is more likely to explain a substantial proportion of the variance in
glucose levels [11, 12]. The medical socioeconomic strain of the disease is increased by its com-
plications [13]. Identification of a large number of common and rare genetic variants impli-
cated in glucose metabolism contributes to translate the genetic information to the clinical
practice and improve risk prediction.
Genetic risk models for type 2 diabetes based on both cross-sectional and longitudinal stud-
ies have been developed [14, 15]. The little observed clinical value of genetic testing for identifi-
cation of individuals prone to develop impaired glucose metabolism can be improved in the
future with new sequencing techniques and identification of low and rare variants with larger
effect sizes[14]. Evaluation of the cumulative variant effect of glucose risk loci on glucose levels
could give a good estimation for pre-diabetic status as well as better control and prevention.
This is of particular interest as based on recent estimations from IDF, 415 million people have
diabetes in the world and there were 608,800 cases of diabetes in Greece in 2015 (http://www.
idf.org/membership/eur/greece). Over the last 30 years, the number of diabetic individuals has
at least quadrupled. It is imperative to focus our research on ways that could detect individuals
at risk of developing diabetes, by identifying them when they are in the pre-diabetic or border-
line state. If undiagnosed or untreated, prediabetes can develop into type 2 diabetes, which is
not fully reversible and is a global problem closely tied to obesity.
Here we address the role of the association of known glucose-raising genetic variants with
glucose levels. We sought to evaluate the cumulative effect of the known variants on glucose




Our sample consisted of 2594 individuals from Greek origin individuals, aged 57.1 ± 13.6
years old. The sample was drawn from the THISEAS (The Hellenic Study of Interactions
between SNPs and Eating in Atherosclerosis Susceptibility) [16, 17] and GOMAP (Genetic
Overlap of Metabolic and Psychiatric Diseases) studies. 1434 individuals were included from
the THISEAS and 1160 individuals for the GOMAP study, all diabetes-free adult individuals of
Greek ancestry (S1 Table). Association analyses were undertaken in individuals deriving from
each study separately. Meta-analysis was carried out in the GOMAP and THISEAS studies. All
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participants were informed both verbally and in a written consent form [16]. The studies had
the approval of the Ethics Committee of Harokopio University of Athens.
Adiposity and biochemical measurements
The enzymatic colorimetric assay (ACE analyzer) was used for glucose levels measurements in
THISEAS and GOMAP studies. Venus serum was used for glucose levels. Individuals with
type 2 diabetes were excluded based on their medical history; self-reported cases in THISEAS.
We also excluded individuals with fasting glucose levels more than 7 mmol/L and random glu-
cose levels more than 11 mmol/L.
Genotyping
Genomic DNA was extracted from whole blood using the iPrep PureLink gDNA Blood Kit-
Invitrogen for the GOMAP study and by using the salting-out method for the THISEAS study
[18]. DNA samples were genotyped using the Illumina Metabochip for the THISEAS study
and using the Illumina HumanCoreExomeChip at the Wellcome Trust Sanger Institute, Hinx-
ton, UK. The genotype calling algorithms were GenoSNP and GenCall for THISEAS and
GOMAP studies respectively. For both studies we excluded individuals with sample call
rate< 95%, genome-wide heterozygosity higher than ± 3SD, sex discrepancies, ethnic outliers
identified by multidimensional scaling (MDS) using PLINK[19]. In THISEAS study four SNPs
(rs2657879, rs2302593, rs7708285 and rs10830963) failed the 98% call rate threshold and were
replaced by imputed data. Imputation was performed using the cosmopolitan 1000 Genomes
panel (http://www.1000genomes.org/) and IMPUTE2 [20]. Prior phasing was done using
SHAPEIT [21]. In the GOMAP study twelve SNPs failed the 98% call rate threshold and were
replaced by imputed data. Imputation was performed using a 3-way reference panel (1000
Genomes (http://www.1000genomes.org/), UK10K (http://www.uk10k.org/) and MANOLIS
study). Estimated probabilities for these SNPs were converted to best-guess genotypes using
gtool (http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html). In the imputed format
each SNP is represented as a set of three probabilities which corresponds to allele pairs AA, AB
and BB. Using a calling threshold cutoff for the probability values (info: 0.9), probabilities for
each individual were transformed to best-guess genotypes using Gtool (http://www.well.ox.ac.
uk/~cfreeman/software/gwas/gtool.html). The genotypes are expressed as pairs of 1, 2, 0
where 1 corresponds to allele A from GEN file and 2 corresponds to allele B. If none of the
probabilities are over the calling threshold then the pair is unknown, coded as 0 0. The defined
threshold for calling genotypes (info: 0.9) was used in order to calculate for missing data. The
info measure takes the value 1 if all genotypes are completely certain, and the value 0 if the
genotype probabilities for each sample are completely uncertain.
Genetic risk score (GRS) modelling
In order to investigate the cumulative effects of known glucose-raising genetic variants, a
genetic risk score was constructed (GRS). We included the public available variants associated
with glucose levels, identified by the MAGIC (the Meta-Analyses of Glucose and Insulin-related
traits Consortium) effort [4, 22]. We calculated the GRS for each individual by summing the
number of effect allele of the 36 SNPs they are carrying. We also modelled a weighted genetic
risk score. The wGRS was calculated as the sum of the 36 risk alleles, weighted by the published
effect sizes [4]. We further addressed the possible overfitting issue, as THISEAS study was part
of the discovery effort, where the weights for the wGRS were taken from. We removed the effect
of this particular sample, by using mathematical formulas to simulate a situation where this
sample is excluded from the meta-analysis, and obtained corrected beta estimates [23]. For the
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calculation of the weighted scores in THISEAS study, only corrected effect sizes were used. We
present the range of the possible number of weighted glucose-increasing alleles, by dividing the
score by the average effect size of the 36 SNPs for each individual [24]. This is a transformation
of the wGRS so that the range equalled that of the unweighted score.
Statistical analysis
We used PLINK [19] assuming an additive genetic model to investigate the association of the
36 SNPs on glucose levels in both studies. We conducted an inverse variance weighted meta-
analysis in a sample of individuals of Greek ancestry. GWAMA (Genome-Wide Association
Meta-Analysis) was used for the meta-analysis performed for the two studies [25]. Statistical
analysis was performed using R version 3.1.1. We present continuous variables as mean ± stan-
dard deviation (SD). The coefficient of determination (R2) was used to express the proportion
of total variation explained by the GRS and the wGRS. We used t-test to compare the differ-
ences between two means.
Regression coefficients derived from the linear regression models testing for the association
of the scores with glucose levels, express the increase of glucose levels per 1-unit increase in the
genetic score. An inverse variance weighted meta-analysis for the association of the scores
with glucose levels was performed for the two studies. The reported p values were based on
two-sided tests and for the associations assessed adjustments for age, sex and BMI were
applied. For the association analyses the statistical significance level is set at p0.05.
We used Quanto v1.2.4, for power calculations (http://hydra.usc.edu/gxe/). We had 80%
power to detect a 0.045 mmol/L change in glucose levels under the effect of the genetic risk
score (S1 Fig).
Results
Several of the variants corresponding to previously identified MAGIC loci also showed evi-
dence for association with glucose levels in our meta-analysis with adjustments used by large-
scale meta-analyses for glycemic traits[26]. Nominal associations were observed at the
SLC30A8 (β ± SE: 0.053 ± 0.021, p = 0.013), PROX1 (β±SE: 0.043±0019, p = 0.027), MTNR1B
(β±SE: 0.048±022, p = 0.03), ADRA2A (β±SE: 0.074±035, p = 0.034), G6PC2 (β±SE: 0.046±022,
p = 0.035) and LPIN3 (β±SE: 0.058±0027, p = 0.035) loci, after adjusting for age and sex (S2, S4
and S6 Tables, S4 Fig). The majority of the investigated variants (30 out of 36) had consistent
direction of effect between the meta-analysis of the THISEAS and GOMAP studies and the
MAGIC [4] meta-analysis (binomial sign test p = 6.96e-05). Nominally significant associations
were observed after adjusting for age, sex and BMI for MTNR1B, ADRA2A, SLC30A8, PDX1,
FEN1, G6PC2 and CDKAL1 loci (S3, S5 and S7 Tables).
Association of the GRS and wGRS scores with glucose levels were also investigated. We
observed positive correlation of the GRS and wGRS with glucose levels (mmol/L) in diabetes-
free individuals for the THISEAS and GOMAP studies (S2 and S3 Figs). Both scores were sig-
nificantly associated with higher glucose levels, as expected. For each increasing risk allele in
an individual’s GRS, glucose levels were increased by 0.019 mmol/L: β ± SE: 0.019 ± 0.003,
P = 1.41e-9. For each increment point in an individual’s wGRS, glucose levels were increased
by 0.016 mmol/L: β ± SE: 0.016 ± 0.003, P = 3.75e-8 (Tables 1 and 2). Our results indicate no
substantial difference regarding the increasing effect of the two scores reflected by the beta
value. Forest plots reporting the effect size of the GRS and wGRS in both cohorts as well as in
the meta-analysis are shown in Fig 1.
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The difference in mean glucose levels between subjects in the highest tertile and those in
the lower tertile was 0.12191 mmol/L, P = 2.30 x10-3). Linear regression models for glucose lev-
els estimation suggested the GRS account for 6.35% of the variance in glucose levels (Fig 2).
Descriptive characteristics of the study cohorts are given in S1 Table. The mean GRS and
wGRS are 37.347 ± 3.686 and 38.729 ± 4.388 points respectively for the diabetes-free individu-
als from the THISEAS study and 37.651 ± 3.708 and 39.214 ± 4.134 points respectively for the
diabetes-free individuals from the GOMAP study.
Discussion
We constructed unweighted and weighted genetic risk scores based on 36 known variants
associated with glucose levels [4]. Our purpose was to investigate whether these genetic scores
are associated with increased glucose levels and could predict impaired glucose metabolism in
a sample of the Greek population.
Many of the previously published variants associated with glucose levels also showed evi-
dence of association in the present meta-analysis, fact that supports the investigation of their
cumulative effect on glucose levels by using a genetic risk score in our population.
Given that most common risk variants identified until now have modest effects on glucose
levels, we ought to investigate the cumulative effect of these variants on glucose levels. We con-
ducted meta-analysis of the genetic scores using data from diabetes-free individuals from the
THISEAS and GOMAP studies. The derived GRS and wGRS scores were associated with
increased glucose levels.
There are some limitations that should be mentioned. The established variants associated
with increased glucose levels used for the scores, explain only a small proportion of the vari-
ance in glucose levels. The observed lower beta estimate of the GRS for the GOMAP study
could be attributed to the hospital-based recruitment, opposite to the THISEAS study, where
volunteers were recruited from the general population. Furthermore, another limitation of this
Table 1. Associations of the unweighted Genetic Risk Score (GRS) and the weighted Genetic Risk Score (wGRS) with glucose levels for the meta-
analysis of the GOMAP and THISEAS studies a.
Scores β SE beta_95L beta_95U z p-value i2 N
GRS36 0.018 0.004 0.011 0.025 4.910 9.29E-07 0.624 2216
wGRS36 0.016 0.003 0.010 0.021 5.480 4.35E-08 0.000 2216
aAdjusted for age and sex
Beta coefficient and standard error for the estimated difference in glucose (mmol/L per 1-unit increase in the scores GRS and wGRS.
i2: Heterogeneity index I2 by Higgins et al. 2003.
N: indicates the sample size. The slight difference in sample size is due to missing BMI values in the studies.
https://doi.org/10.1371/journal.pone.0186669.t001
Table 2. Associations of the unweighted Genetic Risk Score (GRS) and the weighted Genetic Risk Score (wGRS) with glucose levels for the meta-
analysis of the GOMAP and THISEAS studies b.
Scores β SE beta_95L beta_95U z p-value i2 N
GRS36 0.019 0.003 0.013 0.025 6.060 1.41E-09 0.042 2160
wGRS36 0.016 0.003 0.010 0.022 5.506 3.75E-08 0.125 2160
bAdjusted for age, sex and BMI.
Beta coefficient and standard error for the estimated difference in glucose (mmol/L per 1-unit increase in the scores GRS and wGRS.
i2: Heterogeneity index I2 by Higgins et al. 2003.
N: indicates the sample size. The slight difference in sample size is due to missing BMI values in the studies.
https://doi.org/10.1371/journal.pone.0186669.t002
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study is that individuals from the THISEAS study were included in the discovery meta-analysis
of Scott et al., which identified 20 out of the 36, but not all glucose associated variants, which
were used for the generation of the genetic risk score presented in the current manuscript [27].
To further address this issue, we performed the analyses for the wGRS in THISEAS study,
using corrected estimates [23]. Also, observational studies, especially cross-sectional study
designs are characterized by limited ability to offer causality or of predictive value inferences.
Furthermore, gene-gene and gene-environment interactions should be taken into account in
order to increase the glucose levels estimation ability of a genetic risk score.
Fig 1. Forest plots of the Meta-Analysis results. Forest plots showing the beta estimates and confidence
intervals of the A. GRS and B. wGRS association in the different populations studied in the discovery cohorts
and the meta-analysis fixed model results. An inverse variance weighted meta-analysis was performed.
https://doi.org/10.1371/journal.pone.0186669.g001
Fig 2. Distribution of individuals in every genotype score group and cumulative effects of the risk
alleles from the 36 SNPs for glucose levels. The bar plots show the average and standard error of glucose
in mmol/L for each genotype score group distribution of the genetic risk score.
https://doi.org/10.1371/journal.pone.0186669.g002
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In summary we found that both GRS and wGRS based on 36 well-established risk loci were
significantly associated with glucose levels. We observed that the allele frequency of the established
variants in the Greek population is in accordance with what is reported by MAGIC for the Euro-
pean populations. To this end it is generally anticipated that ongoing imputation and next-gener-
ation sequencing-based studies will identify further variants affecting blood glucose levels and
increase the estimated variation in glucose levels attributed to genetics. It is possible that addition
of a larger number of common and low frequency variants could improve risk prediction.
Genetic Risk Score methods when generalized could provide improved risk assessment and
lead to personalized preventive care. Studying the genetic risk scores for common diseases in
the general population is not straight-forward. It is also expected that genotypes individually
have small effects for a complex diseases, such as diabetes. Investigating the drug response
based on genotypes and stratifying individuals based on their genetic background could yield
in a more effective treatment. By identifying individuals at risk of developing diabetes based
on their GRS, clinicians could more accurately assess a patient’s unique risk of developing dia-
betes and therefore recommend personalized screening methods. In the era of personalized
medicine incorporation of genetic risk scores could potentially have important clinical utility.
In total, a genetic risk score method could categorize individuals based on their clinical
risk, by using many variants deriving from multiple genes and include them in a simpler
model. The genetic scores created could be promising for improving risk stratification. Appli-
cation of screening individuals for predisposing genetic variants, reliably associated with gly-
caemic traits, could contribute to better recommendations for glucose homeostasis control.
Supporting information
S1 Fig. Estimated power of the analyses for alpha 0.05. Lines represent the different power
values to detect the effect in the model for the association of the weighted genetic risk score
(GRS) with the trait. Calculations were performed using Quanto v1.2.4.
(TIF)
S2 Fig. Scatterplot of the positive correlation between the genetic risk scores and glucose
levels (mmol/L) in the GOMAP study. A. unweighted genetic risk score (GRS) and glucose
levels (mmol/L) and B. weighted genetic risk score (wGRS) and glucose levels (mmol/L).
(TIF)
S3 Fig. Scatterplot of the positive correlation between the genetic risk scores and glucose
levels (mmol/L) in the THISEAS study. A. unweighted genetic risk score (GRS) and glucose
levels (mmol/L) and B. weighted genetic risk score (wGRS) and glucose levels (mmol/L).
(TIF)
S4 Fig. Meta-analysis association results for glucose levels associated loci with glucose lev-
els (mmol/L). Adjusted for age and sex, x-axis: Gene name, y-axis: -logPvalue.
(TIF)
S1 Table. Study-specific descriptive statistics of the cohorts. Age, weighted Genetic Risk
Score (wGRS), unweighted Genetic Risk Score (GRS) and Glucose (mmol/L). Data are pre-
sented as means ± SD for the total sample.
(XLSX)
S2 Table. THISEAS association summary statistics for glucose levels associated loci with
glucose levels. Effect sizes (beta) and SE are given for Glucose (mmol/L), Imputation quality:
info > 0.97.
Chr = chromosome, bp = base pairs, EAF = effect allele frequency, SE = standard error.
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Allelic test p, beta and SE are shown for each single SNP.
Effect sizes (beta) are reported for the effect allele.
Results were obtained using linear regression models assuming an additive effect. Adjust-
ments: age and sex.
EAF: Effect Allele Frequency, HWE: Hardy Weinberg Equilibrium.
(XLSX)
S3 Table. THISEAS association summary statistics for glucose levels associated loci with
glucose levels. Effect sizes (beta) and SE are given for Glucose (mmol/L), Imputation quality:
info > 0.97.
Chr = chromosome, bp = base pairs, EAF = effect allele frequency, SE = standard error.
Allelic test p, beta and SE are shown for each single SNP.
Effect sizes (beta) are reported for the effect allele.
Results were obtained using linear regression models assuming an additive effect. Adjust-
ments: age, sex and BMI.
EAF: Effect Allele Frequency, HWE: Hardy Weinberg Equilibrium.
(XLSX)
S4 Table. GOMAP association summary statistics for glucose levels associated loci with
glucose levels. Effect sizes (beta) and SE are given for Glucose (mmol/L), Imputation quality:
info > 0.97.
Chr = chromosome, bp = base pairs, EAF = effect allele frequency, SE = standard error.
Allelic test p, beta and SE are shown for each single SNP.
Effect sizes (beta) are reported for the effect allele.
Results were obtained using linear regression models assuming an additive effect. Adjust-
ments: age and sex.
EAF: Effect Allele Frequency, HWE: Hardy Weinberg Equilibrium.
(XLSX)
S5 Table. GOMAP association summary statistics for glucose levels associated loci with
glucose levels. Effect sizes (beta) and SE are given for Glucose (mmol/L), Imputation quality:
info > 0.97.
Chr = chromosome, bp = base pairs, EAF = effect allele frequency, SE = standard error.
Allelic test p, beta and SE are shown for each single SNP.
Effect sizes (beta) are reported for the effect allele.
Results were obtained using linear regression models assuming an additive effect. Adjust-
ments: age, sex and BMI.
EAF: Effect Allele Frequency, HWE: Hardy Weinberg Equilibrium.
(XLSX)
S6 Table. Meta-analysis association results for glucose levels associated loci with glucose
levels. Effect sizes (β) and se are given for Glucose (mmol/L).
Allelic test p, be and se are shown for each single SNP.
Effect sizes (β) are reported for the effect allele.
Adjustments: age and sex.
An inverse variance weighted meta-analysis was performed.
(XLSX)
S7 Table. Meta-analysis association results for glucose levels associated loci with glucose
levels. Effect sizes (β) and se are given for Glucose (mmol/L).
Allelic test p, be and se are shown for each single SNP.
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Effect sizes (β) are reported for the effect allele.
Adjustments: age, sex and BMI.
An inverse variance weighted meta-analysis was performed.
(XLSX)
S8 Table. Associationsa analyses of the Genetic Risk Scores with glucose levels. aAdjusted
for age and sex.
bBeta coefficient and standard error for the estimated difference in glucose (mmol/L) values
per 1-unit increase in the genetic risk scores (GRS and wGRS respectively -A and B-).
bN indicates the sample size.
(XLSX)
S9 Table. Associationsa analyses of the Genetic Risk Scores with glucose levels. aAdjusted
for age, sex and BMI.
bBeta coefficient and standard error for the estimated difference in glucose (mmol/L) values
per 1-unit increase in the genetic risk scores (GRS and wGRS respectively -A and B-).
bN indicates the sample size.
(XLSX)
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